Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

CYCC

Cyclacel Pharmaceuticals (CYCC)

Cyclacel Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CYCC
DateTimeSourceHeadlineSymbolCompany
04/01/202501:01GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David LazarNASDAQ:CYCCCyclacel Pharmaceuticals Inc
06/12/202408:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating CostsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
15/11/202408:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross ProceedsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
14/11/202404:22GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross ProceedsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
13/11/202408:45GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business UpdateNASDAQ:CYCCCyclacel Pharmaceuticals Inc
25/10/202400:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard RuleNASDAQ:CYCCCyclacel Pharmaceuticals Inc
24/10/202400:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR SymposiumNASDAQ:CYCCCyclacel Pharmaceuticals Inc
10/10/202400:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR SymposiumNASDAQ:CYCCCyclacel Pharmaceuticals Inc
25/09/202423:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 StudyNASDAQ:CYCCCyclacel Pharmaceuticals Inc
04/09/202423:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:CYCCCyclacel Pharmaceuticals Inc
03/09/202423:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting LetterNASDAQ:CYCCCyclacel Pharmaceuticals Inc
15/08/202406:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business UpdateNASDAQ:CYCCCyclacel Pharmaceuticals Inc
07/08/202423:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial ResultsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
26/06/202423:15GlobeNewswire Inc.Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical CompositionsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
04/06/202422:00GlobeNewswire Inc.Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual MeetingNASDAQ:CYCCCyclacel Pharmaceuticals Inc
03/06/202422:00GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for CancerNASDAQ:CYCCCyclacel Pharmaceuticals Inc
15/05/202406:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business UpdateNASDAQ:CYCCCyclacel Pharmaceuticals Inc
08/05/202423:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial ResultsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
03/05/202406:30GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ RulesNASDAQ:CYCCCyclacel Pharmaceuticals Inc
01/05/202403:51AllPennyStocks.com$8 Million Private Placement Announcement Sends Biotech FlyingNASDAQ:CYCCCyclacel Pharmaceuticals Inc
30/04/202421:00GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:CYCCCyclacel Pharmaceuticals Inc
02/04/202400:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for CancerNASDAQ:CYCCCyclacel Pharmaceuticals Inc
20/03/202407:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:CYCCCyclacel Pharmaceuticals Inc
19/03/202422:27IH Market NewsUS Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices RetreatNASDAQ:CYCCCyclacel Pharmaceuticals Inc
14/03/202407:05GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
08/03/202401:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:CYCCCyclacel Pharmaceuticals Inc
07/03/202401:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax CreditNASDAQ:CYCCCyclacel Pharmaceuticals Inc
21/02/202401:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor ConferenceNASDAQ:CYCCCyclacel Pharmaceuticals Inc
31/01/202401:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical OfficerNASDAQ:CYCCCyclacel Pharmaceuticals Inc
19/12/202301:00GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP DeletionsNASDAQ:CYCCCyclacel Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:CYCC